

# **Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)**

<https://marketpublishers.com/r/P52BEA32923EEN.html>

Date: January 2024

Pages: 390

Price: US\$ 4,799.00 (Single User License)

ID: P52BEA32923EEN

## **Abstracts**

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)

Report Link: <https://www.rootsanalysis.com/reports/peptide-therapeutics-manufacturing/305.html>

The peptide synthesis market is expected to reach USD 2.5 billion by 2023 anticipated to grow at a CAGR of 5.46% during the forecast period 2023-2035.

Peptides function as signaling molecules that bind to specific receptors on cell surfaces,

initiating intracellular effects that regulate physiological functions and metabolic synthesis of various components. Their significance as potential therapeutics has increased due to improved metabolic stability, target specificity, and affinity. Unlike small molecule drugs and biologics, peptide-based therapeutics pose unique challenges in pharmacological research, analytical/process development, impurity research, and structure recognition. The peptide synthesis market has undergone significant evolution recently, driven by the rising popularity of peptide therapeutics. Currently, more than 80 peptide therapeutics have received global approval for treating various chronic diseases such as cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis. Additionally, since 2015, over 630 clinical trials have been conducted to assess the therapeutic efficacy of peptide-based therapies. Furthermore, increased research activity and demand for peptide-based treatments have prompted developers to enhance their capabilities and upgrade manufacturing equipment. However, peptide synthesis encounters challenges such as production capacity shortages, leading developers to outsource complex manufacturing processes to contract service providers to reduce costs and time to market. Pharmaceutical and biotechnology firms are actively partnering with contract manufacturing organizations (CMOs) offering advanced technology platforms to improve the bioavailability of peptide drugs and enhance synthesis efficacy. The demand for outsourcing surged with the introduction of semaglutide generics into the peptide synthesis market. Notably, the demand for GLP-1 peptide API contract manufacturing increased significantly at an annual rate of 37% during 2017-2023 due to its benefits in treating metabolic disorders like type II diabetes and obesity. These factors present promising opportunities for contract manufacturers in the peptide synthesis market in the foreseeable future.

## Report Coverage

The report comprehensively examines the peptide synthesis market based on type of synthesis method used, type of chemical synthesis method, company (CMO) size and key geographical regions.

It thoroughly analyzes market influences such as drivers, restraints, opportunities, and challenges, while evaluating competitive landscapes for top players. Forecasts are provided for segment revenues across major regions.

An extensive assessment of the current market landscape of contract manufacturers offering peptide synthesis services, covering various relevant parameters such as establishment year, entry year into peptide API manufacturing, company size (employee count), headquarters location, product

type (API, intermediates, FDF / fill-finish), API type, services provided, peptide synthesis method, peptide modification type, purification technology, regulatory certifications, geographical presence, and location of peptide API manufacturing facilities.

Detailed evaluation of the competitiveness of peptide synthesis contract manufacturers, considering supplier strength and company competitiveness regarding API type, service offering, synthesis method, purification technique, operational scale, and geographical presence. Additionally, the number of peptide modification services offered is also taken into account. This evaluation includes a comprehensive review of recent developments and initiatives undertaken by contract manufacturers in the peptide synthesis industry, focusing on partnerships, collaborations, and expansion initiatives from 2014 to October 2023.

In-depth analysis of ongoing and planned studies focused on peptide therapeutics, covering various parameters such as trial registration year, number of enrolled patients, trial phase, status, study design, sponsor/collaborator type, therapeutic area, mechanism of action, clinical trial centers, geography, and patient population.

Detailed examination of the capabilities of peptide synthesis companies in different regions, considering parameters like the number of Contract Manufacturing Organizations (CMOs), clinical sites, clinical trials, enrolled patients, peptide manufacturing facilities, demand for peptide therapeutics, and installed capacity.

Informed estimates of the annual commercial and clinical demand for peptide therapeutics based on parameters such as target patient population, dosing frequency, and dose strength.

Estimate of the global installed capacity of contract manufacturers in the peptide synthesis market, considering data reported by industry stakeholders and factoring in the distribution of peptide production capacity among companies of different sizes (small, mid-sized, and large), operational scale (preclinical/clinical and commercial), location of manufacturing facility (North America, Europe, and Asia Pacific), and synthesis method (solid phase peptide synthesis and liquid phase peptide synthesis).

Analysis highlighting potential strategic partners based on the likelihood of collaborating with peptide therapeutics developers, shortlisted considering parameters like pipeline strength, pipeline maturity, year of establishment, and company size.

Qualitative examination outlining the key factors that peptide drug developers must consider when deciding whether to produce their products in-house or engage the services of a Contract Manufacturing Organization (CMO).

In-depth, region-specific analysis of the total cost of ownership associated with engaging a peptide contract manufacturing service provider, providing an estimate of both direct and indirect expenses across 10 relevant parameters over a 20-year timeframe.

Review of regulatory guidelines concerning peptide synthesis, focusing on variations observed across different regions such as the US, Europe, Australia, China, India, Japan, and South Korea. This discussion also addresses the regulatory challenges faced by peptide synthesis companies.

Discussion on industry-related trends, key drivers, and challenges within the peptide synthesis sector, structured within a SWOT framework, including a Harvey ball assessment to highlight the relative impact of each SWOT parameter on industry dynamics.

## Key Market Companies

AmbioPharm

CPC Scientific

Creative Peptides

CSBio

Bachem

BCN Peptide

CordenPharma

Senn Chemicals

PolyPeptide

Auspep

Chinese Peptide Company

Hybio Pharmaceuticals

Peptide Institute

ScinoPharm

## Contents

### 1. PREFACE

- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines

### 2. RESEARCH METHODOLOGY

- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Considerations
  - 2.6.1. Demographics
  - 2.6.2. Economic Factors
  - 2.6.3. Government Regulations
  - 2.6.4. Supply Chain
  - 2.6.5. COVID Impact / Related Factors
  - 2.6.6. Market Access
  - 2.6.7. Healthcare Policies
  - 2.6.8. Industry Consolidation
- 2.7. Key Market Segmentations

### 3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

- 3.1. Chapter Overview
- 3.2. Market Dynamics
  - 3.2.1. Time Period
    - 3.2.1.1. Historical Trends
    - 3.2.1.2. Current and Forecasted Estimates
  - 3.2.2. Currency Coverage
    - 3.2.2.1. Overview of Major Currencies Affecting the Market
    - 3.2.2.2. Impact of Currency Fluctuations on the Industry

### 3.2.3. Foreign Exchange Impact

3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market

3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

### 3.2.4. Recession

3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt

3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

### 3.2.5. Inflation

3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

3.2.5.2. Potential Impact of Inflation on the Market Evolution

## 4. EXECUTIVE SUMMARY

## 5. INTRODUCTION

### 5.1. Chapter Overview

### 5.2. Overview of Peptides

5.2.1. Structural Analysis of Peptides

5.2.2. Classification of Peptides

5.2.3. Peptide Synthesis

5.2.4. Emerging Technologies for Peptide Synthesis

5.2.5. Peptide Modification

5.2.5.1. N-terminal Modification

5.2.5.2. Internal Modification

5.2.5.3. C-terminal Modification

5.2.5.4. Other Modifications

5.2.6. Peptide Purification

5.2.6.1. Peptide Purity Guidelines

### 5.3. Overview of Contract Manufacturing

5.3.1. Need for Outsourcing in the Peptide Manufacturing Industry

5.3.2. General Considerations for Selecting a CMO Partner

5.3.3. Advantages of Outsourcing Manufacturing Operations

5.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing

### 5.4. Future Perspectives

## 6. REGULATORY LANDSCAPE

- 6.1. Chapter Overview
- 6.2. Regulatory Scenario: North America
  - 6.2.1. Scenario in The US
    - 6.2.1.1. Overview
    - 6.2.1.2. General Guidelines for Peptide Manufacturing
- 6.3. Regulatory Scenario: Europe
  - 6.3.1. Scenario in Europe
    - 6.3.1.1. Overview
    - 6.3.1.2. General Guidelines
  - 6.3.2. Scenario in The UK
    - 6.3.2.1. Overview
    - 6.3.2.2. General Guidelines for Peptide Manufacturing
- 6.4. Regulatory Scenario: Asia-Pacific
  - 6.4.1. Overview
  - 6.4.2. Scenario in Australian
    - 6.4.2.1. General Guidelines for Peptide Manufacturing
  - 6.4.3. Scenario in Chinese
    - 6.4.3.1. General Guidelines for Peptide Manufacturing
    - 6.4.3.2. Tax-related Modifications in Chinese Pharmaceutical Sector
  - 6.4.4. Scenario in India
    - 6.4.4.1. General Guidelines for Peptide Manufacturing
    - 6.4.4.2. Tax-related Modifications in Indian Pharmaceutical Sector
  - 6.4.5. Scenario in Japan
    - 6.4.5.1. General Guidelines for Peptide Manufacturing
  - 6.4.6. Scenario in South Korea
    - 6.4.6.1. General Guidelines for Peptide Manufacturing
- 6.5. Challenges Associated with Peptide Manufacturing

## **7. MARKET LANDSCAPE**

- 7.1 Chapter Overview
- 7.2 Peptide Therapeutics Contract API Manufacturing: Overall Market Landscape
  - 7.2.1. Analysis by Year of Establishment
  - 7.2.2. Analysis by Year of Entrance of Peptide API Contract Manufacturers
  - 7.2.3. Analysis by Company Size
  - 7.2.4. Analysis by Location of Headquarters
  - 7.2.5. Analysis by Type of Product
  - 7.2.6. Analysis by Type of API Manufactured
  - 7.2.7. Analysis by Scale of Operation



- 7.2.8. Analysis by Type of Services Offered
- 7.2.9. Analysis by Type of Peptide Synthesis Method
- 7.2.10. Analysis by Type of Peptide Modification
- 7.2.11. Analysis by Type of Purification Technology Used
- 7.2.12. Analysis by Regulatory Certifications and Accreditations
- 7.2.13. Analysis by Geographical Presence
- 7.2.14. Analysis by Location of Peptide API Manufacturing Facilities
- 7.3. List of Custom Peptide Manufacturers

## **8. COMPANY COMPETITIVENESS ANALYSIS**

- 8.1. Chapter Overview
- 8.2. Key Parameters
- 8.3. Methodology
- 8.4. Company Competitiveness Analysis
  - 8.4.1 Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
  - 8.4.2 Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
  - 8.4.2 Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity

## **9. COMPANY PROFILES**

- 9.1 Chapter Overview
- 9.2. Peptide Therapeutics Contract API Manufacturers based in North America
  - 9.2.1. AmbioPharm
    - 9.2.1.1. Company Overview
    - 9.2.1.2. Service Portfolio
    - 9.2.1.3. Manufacturing Facilities and Capabilities
    - 9.2.1.4. Recent Developments and Future Outlook
  - 9.2.2. CPC Scientific
    - 9.2.2.1. Company Overview
    - 9.2.2.2. Service Portfolio
    - 9.2.2.3. Manufacturing Facilities and Capabilities
    - 9.2.2.4. Recent Developments and Future Outlook
  - 9.2.3. Creative Peptides
    - 9.2.3.1. Company Overview
    - 9.2.3.2. Service Portfolio

- 9.2.3.3. Manufacturing Facilities and Capabilities
- 9.2.3.4. Recent Developments and Future Outlook
- 9.2.4. CSBio
  - 9.2.4.1. Company Overview
  - 9.2.4.2. Service Portfolio
  - 9.2.4.3. Manufacturing Facilities and Capabilities
  - 9.2.4.4. Recent Developments and Future Outlook
- 9.3. Peptide Therapeutics Contract API Manufacturers based in Europe
  - 9.3.1. Bachem
    - 9.3.1.1. Company Overview
    - 9.3.1.2. Service Portfolio
    - 9.3.1.3. Manufacturing Facility and Capabilities
    - 9.3.1.4. Recent Developments and Future Outlook
  - 9.3.2. BCN Peptides
    - 9.3.2.1. Company Overview
    - 9.3.2.2. Service Portfolio
    - 9.3.2.3. Manufacturing Facility and Capabilities
    - 9.3.2.4. Recent Development and Future Outlook
  - 9.3.3. CordenPharma
    - 9.3.3.1. Company Overview
    - 9.3.3.2. Service Portfolio
    - 9.3.3.3. Manufacturing Facility and Capabilities
    - 9.3.3.4. Recent Developments and Future Outlook
  - 9.3.4. PolyPeptide
    - 9.3.4.1. Company Overview
    - 9.3.4.2. Service Portfolio
    - 9.3.4.3. Manufacturing Facilities and Capabilities
    - 9.3.4.4. Recent Developments and Future Outlook
  - 9.3.5. Senn Chemicals
    - 9.3.5.1. Company Overview
    - 9.3.5.2. Service Portfolio
    - 9.3.5.3. Manufacturing Facilities and Capabilities
    - 9.3.5.4. Recent Developments and Future Outlook
- 9.4. Peptide Therapeutics Contract API Manufacturers based in Asia-Pacific
  - 9.4.1. Auspep
    - 9.4.1.1. Company Overview
    - 9.4.1.2. Service Portfolio
    - 9.4.1.3. Manufacturing Facilities and Capabilities
    - 9.4.1.4. Recent Developments and Future Outlook

- 9.4.2. Chinese Peptide
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Service Portfolio
  - 9.4.2.3. Manufacturing Facilities and Capabilities
  - 9.4.2.4. Recent Developments and Future Outlook
- 9.4.3. Hybio Pharmaceutical
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Service Portfolio
  - 9.4.3.3. Manufacturing Facilities and Capabilities
  - 9.4.3.4. Recent Developments and Future Outlook
- 9.4.4. Peptide Institute
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Service Portfolio
  - 9.4.4.3. Manufacturing Facilities and Capabilities
  - 9.4.4.4. Recent Developments and Future Outlook
- 9.4.5. ScinoPharm
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Service Portfolio
  - 9.4.5.3. Manufacturing Facilities and Capabilities
  - 9.4.5.4. Recent Developments and Future Outlook

## **10. RECENT DEVELOPMENTS AND INITIATIVES**

- 10.1. Chapter Overview
- 10.2. Partnerships and Collaborations
  - 10.2.1. Partnerships Models
  - 10.2.2. List of Partnerships and Collaborations
  - 10.2.3. Analysis by Year of Partnership
  - 10.2.4. Analysis by Type of Partnership
  - 10.2.5. Analysis by Year and Type of Partnership
  - 10.2.6. Analysis by Company Size and Type of Partnership
  - 10.2.7. Analysis by Scale of Operation
  - 10.2.8. Analysis by Scale of Operation and Type of Partnership
  - 10.2.9. Analysis by Green Chemistry Integration
  - 10.2.10. Most Active Players: Analysis by Number of Partnerships
  - 10.2.11. Analysis by Geography
    - 10.2.11.1. Intercontinental and Intracontinental Agreements
    - 10.2.12.2. Local and International Agreements
- 10.3. Recent Expansion Models

- 10.3.1. Expansion Models
- 10.3.2 List of Recent Expansions
- 10.3.3. Analysis by Year of Expansion
- 10.3.4. Analysis by Type of Expansion
- 10.3.5. Analysis by Year and Type of Expansion
- 10.3.6. Analysis by Location of Expanded Facility (Region)
- 10.3.7. Analysis by Location of Expanded Facility (Country)
- 10.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
- 10.3.9. Most Active Players: Analysis by Number of Expansions
- 10.3.10. Recent Expansions: Analysis by Geography (Country)
- 10.3.11. Recent Expansions: List of Planned Expansions
- 10.4. Emerging Peptide Synthesis Technologies
  - 10.4.1. Chemo-Enzymatic Peptide Synthesis Technology
  - 10.4.2. Continuous Flow Technology
  - 10.4.3. Green Chemistry

## **11. CLINICAL TRIAL ANALYSIS**

- 11.1. Chapter Overview
- 11.2. Scope and Methodology
- 11.3. Peptide Therapeutics: Clinical Trials Analysis
  - 11.3.1. Analysis by Trial Registration Year
  - 11.3.2. Analysis by Number of Patients Enrolled
  - 11.3.3. Analysis by Trial Phase
  - 11.3.4. Analysis by Trial Registration Year and Trial Phase
  - 11.3.5. Analysis by Trial Phase and Patients Enrolled
  - 11.3.6. Analysis by Trial Status
  - 11.3.7. Analysis by Trial Registration Year and Trial Status
  - 11.3.8. Analysis by Therapeutic Area
  - 11.3.9. Analysis by Mechanism of Action
  - 11.3.10. Analysis by Trial Registration Year and Mechanism of Action
  - 11.3.11. Analysis by Type of Sponsor / Collaborator
  - 11.3.12. Analysis by Study Design
    - 11.3.12.1. Analysis by Type of Patient Allocation Model Used
    - 11.3.12.2. Analysis by Type of Trial Masking Adopted
    - 11.3.12.3. Analysis by Type of Intervention
    - 11.3.12.4. Analysis by Trial Purpose
  - 11.3.13. Most Active Players: Analysis by Number of Clinical Trials

#### 11.3.14. Analysis by Geography

11.3.14.1. Analysis of Clinical Trials by Geography

11.3.14.2. Analysis of Clinical Trials by Geography and Trial Status

11.3.14.3. Analysis of Clinical Trials by Geography and Therapeutic Area

11.3.14.4. Analysis of Patients Enrolled by Geography

11.3.14.5. Analysis of Patients Enrolled by Geography and Trial Status

## **12. REGIONAL CAPABILITY ANALYSIS**

12.1. Chapter Overview

12.2. Key Assumptions and Methodology

12.3. Overall Landscape of Peptide Therapeutics Contract API Manufacturing Facilities

12.4. Peptide Therapeutics Contract API Manufacturing Capability in North America

12.5. Peptide Therapeutics Contract API Manufacturing Capability in Europe

12.6. Peptide Therapeutics Contract API Manufacturing Capability in Asia-Pacific

## **13. DEMAND ANALYSIS**

13.1. Chapter Overview

13.2. Assumptions and Methodology

13.3. Peptide Therapeutics Contract API Manufacturing: Overall Annual Demand

13.3.1. Peptide Therapeutics Contract API Manufacturing: Clinical Demand

13.3.1.1. Clinical Demand for Peptide Therapeutics Contract API Manufacturing:  
Analysis by Phase of Development

13.3.2. Peptide Therapeutics Contract API Manufacturing: Commercial Outsourced  
Demand

13.3.2.1. Commercial Demand for Peptide Therapeutics Contract API Manufacturing:  
Analysis by GLP-1 Mechanism of Action

13.3.3. Peptide Therapeutics Contract API Manufacturing: Analysis by Type of Peptide  
API Synthesis

13.3.4. Peptide Therapeutics Contract API Manufacturing: Analysis by Geography

## **14. CAPACITY ANALYSIS**

14.1. Chapter Overview

14.2. Key Assumptions and Methodology

14.3. Peptide Therapeutics Contract API Manufacturing: Global Installed Capacity

14.3.1. Analysis by Company Size

14.3.2. Analysis by Scale of Operation

- 14.3.3. Analysis by Location of Manufacturing Facility
- 14.3.4. Analysis by Company Size and Location of Manufacturing Facility
- 14.3.5 Analysis by Chemical Synthesis Method
- 14.4. Concluding Remarks

## **15. LIKELY PARTNERS ANALYSIS**

- 15.1. Chapter Overview
- 15.2. Scoring Criteria and Key Assumptions
- 15.3. Scope and Methodology
- 15.4. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in North America
  - 15.4.1. Most Likely Partners
  - 15.4.2. Likely Partners
  - 15.4.3. Least Likely Partners
- 15.5. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Europe
  - 15.5.1. Most Likely Partners
  - 15.5.2. Likely Partners
  - 15.5.3. Least Likely Partners
- 15.6. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Asia Pacific and Rest of the World
  - 15.6.1. Most Likely Partners
  - 15.6.2. Likely Partners
  - 15.6.3. Least Likely Partners

## **16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK**

- 16.1. Chapter Overview
- 16.2. Assumptions and Parameter Definitions
- 16.3. Make versus Buy Decision Making Framework
  - 16.3.1. Scenario
  - 16.3.2. Scenario
  - 16.3.3. Scenario
  - 16.3.4. Scenario
- 16.4. Concluding Remarks

## **17. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS**

- 17.1. Chapter Overview
- 17.2. Assumptions and Methodology
- 17.3. Key Parameters
- 17.4. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20
- 17.5. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX And OPEX, Y0 and Y20
  - 17.5.1. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX, Y0
  - 17.5.2. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by OPEX, Y1-Y20

## **18. GLOBAL PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET**

- 18.1. Chapter Overview
- 18.2. Key Assumptions and Methodology
- 18.3. Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
  - 18.3.1. Scenario Analysis
    - 18.3.1.1. Conservative Scenario
    - 18.3.1.2. Optimistic Scenario
- 18.4. Key Market Segmentations

## **19. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD**

- 19.1. Chapter Overview
- 19.2. Key Assumptions and Methodology
- 19.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2023 and 2035
  - 19.3.1. Non-chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
  - 19.3.2. Chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
    - 19.3.2.1 Liquid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
    - 19.3.2.2 Solid Phase Synthesis: Historical Trends (2021-2023) and Forecasted

Estimates (2024-2035)

19.3.2.3 Hybrid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)

19.4. Data Triangulation and Validation

## **20. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY COMPANY SIZE**

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2023 and 2035

20.3.1. Small Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)

20.3.2. Mid-sized Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)

20.3.3. Large Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)

20.4. Data Triangulation and Validation

## **21. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY GEOGRAPHY**

21.1. Chapter Overview

21.2. Assumptions and Methodology

21.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 and 2035

21.3.1. Peptide Therapeutics Contract API Manufacturing Market in North America: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)

21.3.1.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America

21.3.1.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America

21.3.1.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America

21.3.1.4. Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method

21.3.1.5. Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method



21.3.2. Peptide Therapeutics Contract API Manufacturing Market in Europe: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)

21.3.2.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe

21.3.2.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe

21.3.2.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe

21.3.2.4. Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method

21.3.2.5. Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method

21.3.3. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)

21.3.3.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World

21.3.3.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World

21.3.3.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World

21.3.3.4. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method

21.3.3.5. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method

21.4. Data Triangulation and Validation

## **22. SWOT ANALYSIS**

22.1. Chapter Overview

22.2. Strengths

22.3. Weaknesses

22.4. Opportunities

22.5. Threats

22.6. Comparison of SWOT Factors

22.7. Concluding Remarks

## **23. CONCLUSION**

## **24. EXECUTIVE INSIGHTS**

### 24.1. Chapter Overview

### 24.2. Ascendia Pharmaceuticals

#### 24.2.1 Company Snapshot

24.2.2. Interview Transcript: Robert Bloder (Chief Business Officer), Shaukat Ali (Senior Director of Scientific Affairs and Technical Marketing)

### 24.3. Almac

#### 24.3.1 Company Snapshot

#### 24.3.2. Interview Transcript: Alastair Hay (Vice President, Peptides)

### 24.4. NUMAFERM

#### 24.4.1 Company Snapshot

#### 24.4.2. Interview Transcript: Philipp Burling (Chief Financial Officer)

### 24.5. Sekisui XenoTech

#### 24.5.1 Company Snapshot

24.5.2. Interview Transcript: Hideki Kubota (Senior Manager, Peptide Business Project Leader)

### 24.6. Previtalica

#### 24.6.1 Company Snapshot

#### 24.6.2. Interview Transcript: Sergiy Stupka (Founder and Owner)

## **25. APPENDIX I: TABULATED DATA**

## **26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS**

Table 5.1 Comparison of Major Peptide Synthesizing Processes

Table 5.2 Chromatographic Techniques

Table 6.1 Comparison of Regulatory Landscape of China and India

Table 7.1 Peptide Therapeutics Contract API Manufacturers: List of Companies

Table 7.2 Peptide Therapeutics Contract API Manufacturers: Information on Type of API and Scale of Operation

Table 7.3 Peptide Therapeutics Contract API Manufacturers: Information on Type of Services Offered and Peptide Synthesis Method

Table 7.4 Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Modification and Type of Purification Technology Used

Table 7.5 Peptide Therapeutics Contract API Manufacturers: Information on Regulatory Certifications and Accreditations

Table 7.6 List of Custom Peptide Manufacturers

Table 8.1 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity

Table 8.2 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity

Table 8.3 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity

Table 9.1 Leading Peptide Therapeutics Contract API Manufacturers

Table 9.2 AmbioPharm: Company Overview

Table 9.3 AmbioPharm: Overview of Manufacturing Capabilities

Table 9.4 AmbioPharm: Recent Developments and Future Outlook

Table 9.5 CPC Scientific: Company Overview

Table 9.6 CPC Scientific: Overview of Manufacturing Capabilities

Table 9.7 CPC Scientific: Recent Developments and Future Outlook

Table 9.8 Creative Peptides: Company Overview

Table 9.9 Creative Peptides: Overview of Manufacturing Capabilities

Table 9.10 Creative Peptides: Recent Developments and Future Outlook

Table 9.11 CSBio: Company Overview

Table 9.12 CSBio: Overview of Manufacturing Capabilities

Table 9.13 CSBio: Recent Developments and Future Outlook

Table 9.14 Bachem: Company Overview

Table 9.15 Bachem: Overview of Manufacturing Capabilities

Table 9.16 Bachem: Recent Developments and Future Outlook

Table 9.17 BCN Peptides: Company Overview

Table 9.18 BCN Peptides: Overview of Manufacturing Capabilities

Table 9.19 BCN Peptides: Recent Developments and Future Outlook

Table 9.20 CordenPharma: Company Overview

Table 9.21 CordenPharma: Overview of Manufacturing Capabilities

Table 9.22 CordenPharma: Recent Developments and Future Outlook

Table 9.23 PolyPeptide: Company Overview

Table 9.24 PolyPeptide: Overview of Manufacturing Capabilities

Table 9.25 PolyPeptide: Recent Developments and Future Outlook

Table 9.26 Senn Chemicals: Company Overview

Table 9.27 Senn Chemicals: Overview of Manufacturing Capabilities

Table 9.28 Aussep: Company Overview

Table 9.29 Aussep: Overview of Manufacturing Capabilities

Table 9.30 Aussep: Recent Developments and Future Outlook

Table 9.31 Chinese Peptide: Company Overview

Table 9.32 Chinese Peptide: Overview of Manufacturing Capabilities

Table 9.33 Hybio Pharmaceuticals: Company Overview

Table 9.34 Hybio Pharmaceuticals: Overview of Manufacturing Capabilities

Table 9.35 Peptide Institute: Company Overview

Table 9.36 Peptide Institute: Overview of Manufacturing Capabilities

Table 9.37 ScinoPharm: Company Overview

Table 9.38 ScinoPharm: Overview of Manufacturing Capabilities

Table 10.1 Peptide Therapeutics Contract API Manufacturers: List of Partnerships and Collaborations, Pre-2019-2023

Table 10.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)

Table 10.3 Peptide Therapeutics Contract API Manufacturers: List of Recent Expansions, Pre-2019-2023

Table 10.4 Peptide Therapeutics Contract API Manufacturers: List of Planned Upcoming Expansions

Table 14.1 Peptide Therapeutics Contract API Manufacturers: Information on Total Installed Capacity (Sample Dataset)

Table 14.2 Peptide Therapeutics Contract API Manufacturing: Average Capacity based on Company Size (Sample Dataset)

Table 14.3 Peptide Therapeutics Contract API Manufacturing Capacity: Average Share Based on Synthesis Method (Sample Dataset)

Table 14.4 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)

Table 15.1 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America

Table 15.2 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America

Table 15.3 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America

Table 15.4 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe

Table 15.5 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe

Table 15.6 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe

Table 15.7 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World

Table 15.8 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World

Table 15.9 Least Likely Partner Opportunities for Peptide Therapeutics Contract

Manufacturers Based in Asia Pacific and Rest of the World

Table 24.1 Ascendia Pharmaceuticals: Company Snapshot

Table 24.2 Almac: Company Snapshot

Table 24.3 NUMAFERM: Company Snapshot

Table 24.4 Sekisui: Company Snapshot

Table 24.5 Previtalica: Company Snapshot

Table 25.1 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Establishment

Table 25.2 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Entrance

Table 25.3 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Company Size

Table 25.4 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Headquarters

Table 25.5 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Product

Table 25.6 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of API Manufactured

Table 25.7 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Scale of Operation

Table 25.8 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Service Offered

Table 25.9 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Peptide Synthesis Method

Table 25.10 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Chemical Synthesis Method

Table 25.11 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Peptide Modification

Table 25.12 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Purification Technology Used

Table 25.13 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Regulatory Certifications and Accreditations

Table 25.14 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Geographical Presence (Region)

Table 25.15 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)

Table 25.16 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Country)

Table 25.17 Partnerships and Collaborations: Cumulative Year-wise Trend,

Pre-2019-2023

Table 25.18 Partnerships and Collaborations: Distribution by Type of Partnership

Table 25.19 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Table 25.20 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership

Table 25.21 Partnerships and Collaborations: Distribution by Scale of Operation

Table 25.22 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership

Table 25.23 Partnerships and Collaborations: Distribution by Green Chemistry Integration

Table 25.24 Most Active Players: Distribution by Number of Partnerships

Table 25.25 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements

Table 25.26 Partnerships and Collaborations: Local and International Agreements

Table 25.27 Recent Expansions: Cumulative Year-wise Trend of Recent Expansions, Pre-2019-2023

Table 25.28 Recent Expansions: Distribution by Type of Expansion

Table 25.29 Recent Expansions: Distribution by Year and Type of Expansion

Table 25.30 Recent Expansions: Distribution by Location of Expanded Facility (Region)

Table 25.31 Recent Expansions: Distribution by Location of Expanded Facility (Country)

Table 25.32 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion

Table 25.33 Most Active Players: Distribution by Number of Expansions

Table 25.34 Recent Expansions: Distribution by Geography (Country)

Table 25.35 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year

Table 25.36 Clinical Trial Analysis: Year-wise Trend of Number of Patients Enrolled by Trial Registration Year

Table 25.37 Clinical Trial Analysis: Distribution by Trial Phase

Table 25.38 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled

Table 25.39 Clinical Trial Analysis: Distribution by Trial Status

Table 25.40 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Table 25.41 Clinical Trial Analysis: Distribution by Therapeutic Area

Table 25.42 Clinical Trial Analysis: Distribution by Mechanism of Action

Table 25.43 Clinical Trial Analysis: Distribution by Trial Registration Year and Mechanism of Action

Table 25.44 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Table 25.45 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used

Table 25.46 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted

Table 25.47 Clinical Trial Analysis: Distribution by Type of Intervention Model

Table 25.48 Clinical Trial Analysis: Distribution by Trial Purpose

Table 25.49 Most Active Industry Players: Distribution by Number of Clinical Trials

Table 25.50 Most Active Non-industry Players: Distribution by Number of Clinical Trials

Table 25.51 Clinical Trial Analysis: Distribution of Clinical Trials by Geography

Table 25.52 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status

Table 25.53 Clinical Trial Analysis: Distribution by Geography and Therapeutic Area

Table 25.54 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography

Table 25.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status

Table 25.56 Regional Distribution of Peptide Therapeutics Contract API Manufacturing Facilities

Table 25.57 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in North America

Table 25.58 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in Europe

Table 25.59 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia Pacific and Rest of the World

Table 25.60 Global Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)

Table 25.61 Global Clinical Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Future Estimates (2024-2035) (Kilograms)

Table 25.62 Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Phase of Development, 2024 and 2035

Table 25.63 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase I Trials, 2024-2035 (Kilograms)

Table 25.64 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase II Trials, 2024-2035 (Kilograms)

Table 25.65 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase III Trials, 2024-2035 (Kilograms)

Table 25.66 Global Commercial Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)

Table 25.67 Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Mechanism of Action (specific to GLP-1),

Table 25.68 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035)

Table 25.69 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for non-GLP-1 based Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-

Table 25.70 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Type of Peptide Synthesis Method, 2024 and 2035

Table 25.71 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Geography, 2024 and 2035 (Kilograms)

Table 25.72 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)

Table 25.73 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Range of Installed Capacity (liters)

Table 25.74 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Scale of Operation (liters)

Table 25.75 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Location of Manufacturing Facility (liters)

Table 25.76 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing

Table 25.77 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Synthesis Method (liters)

Table 25.78 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20 (USD Million)

Table 25.79 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)

Table 25.80 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)

Table 25.81 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)

Table 25.82 Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Table 25.83 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)

Table 25.84 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)

Table 25.85 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2024 And 2035

Table 25.86 Peptide Therapeutics Contract API Manufacturing Market for Type of Non-



chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD)

Table 25.87 Peptide Therapeutics Contract API Manufacturing Market for Type of Chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates

Table 25.88 Peptide Therapeutics Contract API Manufacturing Market for Liquid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates

Table 25.89 Peptide Therapeutics Contract API Manufacturing Market for Solid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates

Table 25.90 Peptide Therapeutics Contract API Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates

Table 25.91 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2024 And 2035

Table 25.92 Peptide Therapeutics Contract API Manufacturing Market for Small Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-

Table 25.93 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies, Historical Trends (2021-2023) and Forecasted Estimates

Table 25.94 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD)

Table 25.95 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 And 2035

Table 25.96 Peptide Therapeutics Contract API Manufacturing Market in North America, Historical Trends (2021-2024) and Forecasted Estimates (2024-

Table 25.97 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America, 2024-2035 (USD Billion)

Table 25.98 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America, 2024-2035 (USD Billion)

Table 25.99 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America, 2024-2035 (USD Billion)

Table 25.100 Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method, 2024-2035 (USD Billion)

Table 25.101 Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

Table 25.102 Peptide Therapeutics Contract API Manufacturing Market in Europe, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)

Table 25.103 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe, 2024-2035 (USD Billion)

Table 25.104 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe, 2024-2035 (USD Billion)

Table 25.105 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe, 2024-2035 (USD Billion)

Table 25.106 Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method, 2024-2035 (USD Billion)

Table 25.107 Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

Table 25.108 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (2021-2024) and Forecasted Estimates (2024-

Table 25.109 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)

Table 25.110 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)

Table 25.111 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)

Table 25.112 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method, 2024-2035 (USD Billion)

Table 25.113 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Forecast Methodology

Figure 2.3 Research Methodology: Robust Quality Control

Figure 2.4 Research Methodology: Key Market Segmentation

Figure 3.1 Lessons Learnt from Past Recessions

Figure 4.1 Executive Summary: Overall Market Landscape

Figure 4.2 Executive Summary: Recent Developments and Initiatives

Figure 4.3 Executive Summary: Clinical Trial Analysis

Figure 4.4 Executive Summary: Demand Analysis

Figure 4.5 Executive Summary: Capacity Analysis

Figure 4.6 Executive Summary: Total Cost of Ownership

Figure 4.7 Executive Summary: Market Forecast and Opportunity Analysis (I/II)

Figure 4.7 Executive Summary: Market Forecast and Opportunity Analysis (II/II)

Figure 5.1 Methods of Peptide Synthesis

Figure 5.2 Latest Technologies for Peptide Synthesis

Figure 5.3 Peptide Modification Techniques

Figure 5.4 Types of Third-Party Service Providers

Figure 6.1 Regulatory Agencies Governing Peptide Manufacturing in the US

Figure 7.1 Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Establishment

Figure 7.2 Peptide Therapeutics Contract API Manufacturers: Distribution by Year of

Entrance of Peptide API Contract Manufacturers

Figure 7.3 Peptide Therapeutics Contract API Manufacturers: Distribution by Company Size

Figure 7.4 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Headquarters

Figure 7.5 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Product

Figure 7.6 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of API Manufactured

Figure 7.7 Peptide Therapeutics Contract API Manufacturers: Distribution by Scale of Operation

Figure 7.8 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Services Offered

Figure 7.9 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Synthesis Method

Figure 7.10 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Modification

Figure 7.11 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Purification Technology Used

Figure 7.12 Peptide Therapeutics Contract API Manufacturers: Distribution by Regulatory Certifications and Accreditations

Figure 7.13 Peptide Therapeutics Contract API Manufacturers: Distribution by Geographical Presence (Region)

Figure 7.14 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)

Figure 7.15 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Country)

Figure 8.1 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity

Figure 8.2 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity

Figure 8.3 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity

Figure 9.1 AmbioPharm: Service Portfolio

Figure 9.2 CPC Scientific: Service Portfolio

Figure 9.3 Creative peptides: Service Portfolio

Figure 9.4 CSBio: Service Portfolio

Figure 9.5 Bachem: Service Portfolio

Figure 9.6 BCN Peptide: Service Portfolio

Figure 9.7 CordenPharma: Service Portfolio

Figure 9.8 PolyPeptide: Service Portfolio

Figure 9.9 Senn Chemicals: Service Portfolio

Figure 9.10 Auspep: Service Portfolio

Figure 9.11 Chinese Peptide: Service Portfolio

Figure 9.12 Hybio Pharmaceuticals: Service Portfolio

Figure 9.13 Peptide Institute: Service Portfolio

Figure 9.14 ScinoPharm: Service Portfolio

Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2019-2023

Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Figure 10.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership

Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation

Figure 10.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership

Figure 10.7 Partnerships and Collaborations: Distribution by Green Chemistry Integration

Figure 10.8 Most Active Players: Distribution by Number of Partnerships

Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements

Figure 10.10 Partnerships and Collaborations: Local and International Agreements

Figure 10.11 Recent Expansions: Cumulative Year-wise Trend of Recent Expansions, Pre-2019-2023

Figure 10.12 Recent Expansions: Distribution by Type of Expansion

Figure 10.13 Recent Expansions: Distribution by Year and Type of Expansion

Figure 10.14 Recent Expansions: Distribution by Location of Expanded Facility (Region)

Figure 10.15 Recent Expansions: Distribution by Location of Expanded Facility (Country)

Figure 10.16 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion

Figure 10.17 Most Active Players: Distribution by Number of Expansions

Figure 10.18 Recent Expansions: Distribution by Geography (Country)

Figure 10.19 Chemo-Enzymatic Peptide Synthesis Technology: Advantages and Disadvantages

Figure 10.20 Continuous Flow Technology: Advantages and Disadvantages

Figure 10.21 Green Chemistry: Advantages and Disadvantages

Figure 11.1 Clinical Trial Analysis: Scope and Methodology

Figure 11.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year

Figure 11.3 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year

Figure 11.4 Clinical Trial Analysis: Distribution by Trial Phase

Figure 11.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase

Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled

Figure 11.7 Clinical Trial Analysis: Distribution by Trial Status

Figure 11.8 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Figure 11.9 Clinical Trial Analysis: Distribution by Therapeutic Area

Figure 11.10 Clinical Trial Analysis: Distribution by Mechanism of Action

Figure 11.11 Clinical Trial Analysis: Distribution by Trial Registration Year and Mechanism of Action

Figure 11.12 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Figure 11.13 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used

Figure 11.14 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted

Figure 11.15 Clinical Trial Analysis: Distribution by Type of Intervention

Figure 11.16 Clinical Trial Analysis: Distribution by Trial Purpose

Figure 11.17 Most Active Industry Players: Distribution by Number of Clinical Trials

Figure 11.18 Most Active Non-industry Players: Distribution by Number of Clinical Trials

Figure 11.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography

Figure 11.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status

Figure 11.21 Clinical Trial Analysis: Distribution by Geography and Therapeutic Area

Figure 11.22 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography

Figure 11.23 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status

Figure 12.1 Regional Distribution of Peptide Therapeutics Contract API Manufacturing Facilities

Figure 12.2 Regional Capability Analysis: Peptide API Contract Manufacturers in North America

Figure 12.3 Regional Capability Analysis: Peptide API Contract Manufacturers in Europe

Figure 12.4 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia-Pacific

Figure 13.1 Global Demand for Peptide Therapeutics Contract API Manufacturing,

Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)

Figure 13.2 Global Clinical Demand for Peptide Therapeutics Contract API

Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)

Figure 13.3 Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Phase of Development, 2024 and 2035

Figure 13.4 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase I Trials, 2024-2035 (Kilograms)

Figure 13.5 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase II Trials, 2024-2035 (Kilograms)

Figure 13.6 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase III Trials, 2024-2035 (Kilograms)

Figure 13.7 Global Commercial Demand for Peptide Therapeutics Contract API

Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)

Figure 13.8 Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by to GLP-1 Mechanism of Action, 2024 and 2035

Figure 13.9 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)

Figure 13.10 Commercial Demand for Peptide Therapeutics Contract API

Manufacturing for non-GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)

Figure 13.11 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Type of Peptide Synthesis Method, 2024 and 2035 (Kilograms)

Figure 13.12 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Geography, 2024 and 2035 (Kilograms)

Figure 14.1 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size

Figure 14.2 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Range of Installed Capacity (Liters)

Figure 14.3 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Scale of Operation (Liters)

Figure 14.4 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Liters)

Figure 14.5 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing Facility

Figure 14.6 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Synthesis Method (Liters)

Figure 16.1 Make versus Buy Decision Making Framework

Figure 16.2 Make versus Buy Decision Making: Possible Scenario

Figure 17.1 Total Cost of Ownership: Capital Expenditures (CAPEX)

Figure 17.2 Total Cost of Ownership: Operational Expenditures (OPEX)

Figure 17.3 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20 (USD Million)

Figure 17.4 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)

Figure 17.5 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)

Figure 17.6 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)

Figure 18.1 Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 18.2 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)

Figure 18.3 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)

Figure 19.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2024 And 2035

Figure 19.2 Peptide Therapeutics Contract API Manufacturing Market for Non-chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 19.3 Peptide Therapeutics Contract API Manufacturing Market for Chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 19.4 Peptide Therapeutics Contract API Manufacturing Market for Liquid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 19.5 Peptide Therapeutics Contract API Manufacturing Market for Solid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 19.6 Peptide Therapeutics Contract API Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 20.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2024 And 2035

Figure 20.2 Peptide Therapeutics Contract API Manufacturing Market for Small

Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 20.3 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 20.4 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 21.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 And 2035

Figure 21.2 Peptide Therapeutics Contract API Manufacturing Market in North America, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 21.3 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America, 2024-2035 (USD Billion)

Figure 21.4 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America, 2024-2035 (USD Billion)

Figure 21.5 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America, 2024-2035 (USD Billion)

Figure 21.6 Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method, 2024-2035 (USD Billion)

Figure 21.7 Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

Figure 21.8 Peptide Therapeutics Contract API Manufacturing Market in Europe, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 21.9 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe, 2024-2035 (USD Billion)

Figure 21.10 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe, 2024-2035 (USD Billion)

Figure 21.11 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe, 2024-2035 (USD Billion)

Figure 21.12 Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method, 2024-2035 (USD Billion)

Figure 21.13 Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

Figure 21.14 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)

Figure 21.15 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)



Figure 21.16 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)

Figure 21.17 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)

Figure 21.18 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method, 2024-2035 (USD Billion)

Figure 21.19 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

Figure 22.1 Contract Peptide API Manufacturing: SWOT Analysis

Figure 22.2 Comparison of SWOT Factors: Harvey Ball Analysis

Figure 23.1 Concluding Remarks: Overall Market Landscape (I/II)

Figure 23.2 Concluding Remarks: Overall Market Landscape (I/II)

Figure 23.3 Concluding Remarks: Recent Developments (I/II)

Figure 23.4 Concluding Remarks: Recent Developments (I/II)

Figure 23.5 Concluding Remarks: Clinical Trial Analysis

Figure 23.6 Concluding Remarks: Demand Analysis

Figure 23.7 Concluding Remarks: Capacity Analysis

Figure 23.8 Concluding Remarks: Likely Partner Analysis

Figure 23.9 Concluding Remarks: Total Cost of Ownership (USD Million)

Figure 23.10 Concluding Remarks: Market Sizing and Opportunity Analysis

## I would like to order

Product name: Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)

Product link: <https://marketpublishers.com/r/P52BEA32923EEN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P52BEA32923EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970